Bli medlem
Bli medlem

Du är här

2015-12-16

Biotie Therapies Oyj: Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act

BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE December 16,
2015 at 8.00 a.m.

Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act

Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the
"Company") has on December 15, 2015 received a notification in accordance
with Chapter 9, Section 5 of the Finnish Securities Markets Act from Mr.
Samuel D. Isaly on behalf of himself and OrbiMed Advisors LLC, OrbiMed
Capital GP V LLC and OrbiMed Private Investments V, LP as a result of the
implementation of changes to the transparency directive in the Finnish
Securities Market Act.

According to the notification, the total number of Biotie shares owned
directly or through financial instruments by Samuel D. Isaly and entities
under his control was 11.54 per cent of Biotie's total number of shares and
voting rights on November 26,s 2015. Biotie's registered total number of
shares and voting rights amounting to 1,086,940,271 has been used in the
calculation of percentages for the announcement.

Total positions of Samuel D. Isaly and entities under his control subject to
the notification:

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| % of shares and voting rights (total of A) % of shares and voting rights through financial instruments Total of both in % (A + B) |
| (total of B) |
| Resulting situation on the date on which threshold was crossed 6.76 4.78 11.54 |
|or reached |
| Position of previous notification (if applicable) 7.49 N/A N/A |
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Notified details of the resulting situation on the date on which the threshold
was crossed or reached:

A: Shares and voting rights

---------------------------------------------------------------------------------------------
| Class/type of shares Number of shares and voting rights % of shares and voting rights |
| |
|ISIN code (if possible) |
| Direct Indirect Direct Indirect |
| |
| (SMA 9:5) (SMA 9:6 and 9:7) (SMA 9:5) (SMA 9:6 and 9:7) |
| Shares - 51,944,444 - 4.78 |
| |
|(FI0009011571) |
| Shares - 21,493,760 - 1.98 |
| |
|(FI0009011571) |
|represented by |
|268,672 ADSs |
| |
| SUBTOTAL A 73,438,204 6.76 |
---------------------------------------------------------------------------------------------
For further information on the ADSs representing the Company's shares, the
notification refers to the stock exchange release issued by the Company on
June 11, 2015.

B: Financial instruments according to SMA 9:6a

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
| Type of financial instrument Expiration date Exercise/ Physical or cash settlement Number of shares and voting rights % of shares and voting rights |
| |
| Conversion period |
| Warrants entitling to shares (new or treasury shares) Nov 1, 2020 Nov 1, 2015 - Nov 1, 2020 Physical settlement 51,944,444 4.78 |
|(FI0009011571) |
| |
| SUBTOTAL B 51,944,444 4.78 |
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
For further information on the warrants, the notification refers to the stock
exchange release issued by the Company on April 23, 2015.

Full chain of controlled undertakings through which the voting rights and/or
the financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity:

------------------------------------------------------------------------------------------------------------------------------------------------
| Name % of shares and voting rights % of shares and voting rights through financial instruments Total of both |
| Samuel D. Isaly 0 0 0 |
| OrbiMed Advisors LLC 0 0 0 |
| OrbiMed Capital GP V LLC 0 0 0 |
| OrbiMed Private Investments V, LP 6.76 4.78 11.54 |
------------------------------------------------------------------------------------------------------------------------------------------------
According to the notification, Samuel D. Isaly is the managing member of and
owner of a controlling interest in OrbiMed Advisors LLC, which is the sole
managing member of OrbiMed Capital GP V LLC. OrbiMed Capital GP V LLC is the
general partner of OrbiMed Private Investments V, LP. Further, according to
the notification neither Samuel D. Isaly nor any other entity under his
control, other than OrbiMed Private Investments V, LP, holds any shares or
financial instruments in the Company.

In Turku, December 16, 2015

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

DISTRIBUTION:

NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biotie Therapies Oyj via Globenewswire

HUG#1973901

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.